Lupin 2024

current cannabidiol (CBD) marketplace

CHPA: FDA report to congress on CBD underscores need for regulation

CHPA: FDA report to congress on CBD underscores need for regulation

WASHINGTON — The Consumer Healthcare Products Association (CHPA) released the following statement in response to the U.S. Food and Drug Administration (FDA) report to Congress on the current cannabidiol (CBD) marketplace: “While CHPA welcomes additional input from FDA regarding CBD, we’re concerned that the report conclusion further delays any action to better regulate CBD-containing products.

PP_1170x120_10-25-21